Teva Pharmaceutical Industries (TEVA) Financials

$16.18 -0.22 (-1.31%)

As of 03:06 PM Eastern

Annual Income Statements for Teva Pharmaceutical Industries

This table shows Teva Pharmaceutical Industries' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1,573	68	-16,525	-2,399	-999	-3,990	417	-2,446	-559	-1,639
Consolidated Net Income / (Loss)	1,597	311	-16,449	-2,472	-1,000	-4,099	456	-2,499	-615	-1,959
Net Income / (Loss) Continuing Operations	1,597	311	-16,449	-2,472	-1,000	-4,100	456	-2,499	-615	-1,959
Total Pre-Tax Income	2,352	824	-18,379	-2,596	-1,265	-4,406	658	-3,163	-624	-1,284
Total Operating Income	3,352	2,154	-17,484	-1,637	-443	-3,572	1,716	-2,197	433	-303
Total Gross Profit	11,356	11,653	10,615	8,296	7,537	7,726	7,594	6,973	7,645	8,064
Total Revenue	19,652	21,903	21,853	18,271	16,887	16,659	15,878	14,925	15,846	16,544
Operating Revenue	19,652	21,903	21,853	18,271	16,887	16,659	15,878	14,925	15,846	16,544
Total Cost of Revenue	8,296	10,250	11,237	9,975	9,351	8,933	8,284	7,952	8,200	8,481
Operating Cost of Revenue	8,296	10,250	11,237	9,975	9,351	8,933	8,284	7,952	8,200	8,481
Total Operating Expenses	8,004	9,499	28,099	9,933	7,980	11,297	5,879	9,170	7,213	8,366
Selling, General & Admin Expense	1,360	1,390	1,451	1,298	1,192	1,173	1,099	1,180	1,162	1,161
Marketing Expense	3,478	3,583	3,395	2,916	2,614	2,498	2,429	2,265	2,336	2,541
Research & Development Expense	1,525	2,077	1,778	1,213	1,010	997	967	838	953	998
Other Operating Expenses / (Income)	-166	-769	-1,199	-291	-76	-40	-98	-107	-49	-14
Impairment Charge	1,176	2,319	20,338	5,018	1,639	6,130	424	2,400	1,050	1,531
Restructuring Charge	-	-	1,836	987	423	479	341	512	718	1,388
Other Special Charges / (Income)	631	899	500	-1,208	1,178	60	717	2,082	1,043	761
Total Other Income / (Expense), net	-1,000	-1,330	-895	-959	-822	-834	-1,058	-966	-1,057	-981
Other Income / (Expense), net	-1,000	-1,330	-895	-959	-822	-834	-1,058	-966	-1,057	-981
Income Tax Expense	634	521	-1,933	-195	-278	-168	211	-643	-7.00	676
Other Gains / (Losses), net	-121	8.00	-3.00	-71	-13	138	9.00	21	2.00	1.00
Net Income / (Loss) Attributable to Noncontrolling Interest	9.00	-18	-184	-322	-2.00	-109	39	-53	-56	-320
Basic Earnings per Share	$1.84	$0.07	($16.26)	($2.35)	($0.91)	($3.64)	$0.38	($2.20)	($0.50)	($1.45)
Weighted Average Basic Shares Outstanding	855M	955M	1.02B	1.02B	1.09B	1.10B	1.10B	1.11B	1.12B	1.13B
Diluted Earnings per Share	$1.82	$0.07	($16.26)	($2.35)	($0.91)	($3.64)	$0.38	($2.20)	($0.50)	($1.45)
Weighted Average Diluted Shares Outstanding	1.02B	961M	1.02B	1.02B	1.09B	1.10B	1.11B	1.11B	1.12B	1.13B
Weighted Average Basic & Diluted Shares Outstanding	1.02B	1.12B	1.02B	1.02B	1.09B	1.10B	1.10B	1.11B	1.12B	1.13B

This table shows Teva Pharmaceutical Industries' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	56	-1,315	-220	-872	69	464	-139	-846	-437	-217
Consolidated Net Income / (Loss)	58	-1,346	-253	-906	77	467	-419	-874	-390	-276
Net Income / (Loss) Continuing Operations	58	-1,345	-253	-906	77	467	-419	-874	-390	-276
Total Pre-Tax Income	166	-1,198	-272	-923	65	506	-467	-246	-324	-247
Total Operating Income	419	-954	-13	-654	345	755	-218	-5.00	-51	-29
Total Gross Profit	1,669	1,770	1,582	1,796	1,851	2,416	1,771	2,024	2,148	2,121
Total Revenue	3,595	3,883	3,661	3,878	3,850	4,457	3,819	4,164	4,332	4,229
Operating Revenue	3,595	3,883	3,661	3,878	3,850	4,457	3,819	4,164	4,332	4,229
Total Cost of Revenue	1,926	2,113	2,079	2,082	1,999	2,040	2,048	2,140	2,183	2,110
Operating Cost of Revenue	1,926	2,113	2,079	2,082	1,999	2,040	2,048	2,140	2,183	2,110
Total Operating Expenses	1,250	2,722	1,595	2,450	1,506	1,662	1,988	2,030	2,198	2,150
Selling, General & Admin Expense	283	288	296	307	268	291	278	283	298	302
Marketing Expense	539	548	546	603	576	611	608	656	626	651
Research & Development Expense	175	210	234	240	253	226	242	269	240	247
Other Operating Expenses / (Income)	-2.00	-19	-2.00	-33	-9.00	-5.00	1.00	-2.00	-21	8.00
Impairment Charge	24	1,431	178	763	104	5.00	80	461	628	362
Restructuring Charge	36	230	110	108	-	-	673	280	-23	458
Other Special Charges / (Income)	195	34	233	462	314	34	106	83	450	122
Total Other Income / (Expense), net	-252	-245	-260	-268	-280	-249	-250	-241	-272	-218
Other Income / (Expense), net	-252	-245	-260	-268	-280	-249	-250	-241	-272	-218
Income Tax Expense	107	148	-19	-16	-12	40	-52	630	69	29
Net Income / (Loss) Attributable to Noncontrolling Interest	3.00	-32	-33	-35	8.00	4.00	-280	-29	47	-58
Basic Earnings per Share	$0.05	($1.18)	($0.20)	($0.78)	$0.06	$0.42	($0.12)	($0.75)	($0.39)	($0.19)
Weighted Average Basic Shares Outstanding	1.11B	1.11B	1.12B	1.12B	1.12B	1.12B	1.12B	1.13B	1.13B	1.13B
Diluted Earnings per Share	$0.05	($1.18)	($0.20)	($0.78)	$0.06	$0.42	($0.12)	($0.75)	($0.39)	($0.19)
Weighted Average Diluted Shares Outstanding	1.12B	1.11B	1.12B	1.12B	1.14B	1.12B	1.12B	1.13B	1.13B	1.13B
Weighted Average Basic & Diluted Shares Outstanding	1.11B	1.11B	1.12B	1.12B	1.12B	1.12B	1.13B	1.13B	1.13B	1.13B

This table details how cash moves in and out of Teva Pharmaceutical Industries' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	4,720	-5,958	-25	4,607	1,073	202	1,850	636	393	74
Net Cash From Operating Activities	5,542	3,890	2,225	2,446	748	1,216	798	1,590	1,368	1,247
Net Cash From Continuing Operating Activities	5,542	3,890	2,225	6,092	1,644	1,216	2,499	1,590	1,368	1,247
Net Income / (Loss) Continuing Operations	1,597	311	-16,449	-2,472	-1,000	-4,099	456	-2,499	-615	-1,959
Consolidated Net Income / (Loss)	1,597	311	-16,449	-2,472	-1,000	-4,099	456	-2,499	-615	-1,959
Depreciation Expense	1,308	1,524	2,112	1,842	1,722	1,557	1,330	1,308	1,153	1,059
Non-Cash Adjustments To Reconcile Net Income	1,287	2,170	20,525	3,960	2,273	6,542	1,391	2,581	1,158	2,656
Changes in Operating Assets and Liabilities, net	1,350	-115	-3,963	-884	-1,351	-2,784	-678	200	-328	-509
Net Cash From Investing Activities	-5,565	-34,405	3,446	1,866	1,355	863	1,523	656	968	792
Net Cash From Continuing Investing Activities	-5,565	-34,405	3,446	1,866	1,355	863	1,523	656	968	792
Purchase of Property, Plant & Equipment	-772	-901	-874	-651	-525	-578	-562	-548	-526	-498
Acquisitions	-3,309	-36,148	-	-	-	0.00	0.00	-7.00	0.00	-15
Purchase of Investments	-2,003	-481	-200	-119	-8.00	-55	-47	-1.00	-46	-71
Divestitures	-	-	43	-	343	67	311	68	68	43
Sale and/or Maturity of Investments	524	2,002	3,477	890	2.00	12	172	4.00	0.00	40
Other Investing Activities, net	-5.00	1,123	1,000	1,746	1,543	1,417	1,649	1,140	1,472	1,293
Net Cash From Financing Activities	4,805	25,217	-5,750	-3,351	-1,926	-1,885	-2,172	-1,487	-1,913	-1,791
Net Cash From Continuing Financing Activities	4,805	25,217	-5,750	-3,351	-1,926	-1,885	-2,172	-1,487	-1,913	-1,791
Repayment of Debt	-2,699	-1,168	-5,057	-7,763	-2,374	-2,435	-2,381	-1,487	-5,064	-1,649
Payment of Dividends	-1,155	-1,558	-1,199	-22	-52	-	-	0.00	0.00	-78
Issuance of Debt	2,128	27,250	506	4,434	500	550	700	0.00	3,151	0.00
Other Financing Activities, net	388	35	-	-	0.00	-	-491	0.00	0.00	-64
Other Net Changes in Cash	-	-660	54	-	-	8.00	-	-123	-30	-174
Cash Interest Paid	243	290	795	815	840	846	913	948	1,078	1,004
Cash Income Taxes Paid	802	341	106	420	552	709	495	543	298	471

This table details how cash moves in and out of Teva Pharmaceutical Industries' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	167	576	-658	494	-420	977	-236	-733	1,061	-18
Net Cash From Operating Activities	543	973	-145	324	5.00	1,184	-124	103	693	575
Net Cash From Continuing Operating Activities	543	973	-145	324	5.00	1,184	-124	103	693	575
Net Income / (Loss) Continuing Operations	59	-1,347	-253	-906	77	467	-419	-875	-390	-275
Consolidated Net Income / (Loss)	59	-1,347	-253	-906	77	467	-419	-875	-390	-275
Depreciation Expense	321	306	304	300	283	266	272	259	259	269
Non-Cash Adjustments To Reconcile Net Income	65	1,490	225	773	76	84	707	561	557	831
Changes in Operating Assets and Liabilities, net	98	524	-421	157	-431	367	-684	158	267	-250
Net Cash From Investing Activities	147	168	181	302	184	301	144	178	268	202
Net Cash From Continuing Investing Activities	147	168	181	302	184	301	144	178	268	202
Purchase of Property, Plant & Equipment	-122	-142	-139	-119	-149	-119	-124	-97	-148	-129
Purchase of Investments	2.00	1.00	-4.00	-2.00	-38	-2.00	-12	-43	-1.00	-15
Divestitures	2.00	23	2.00	56	10	-	-15	1.00	38	19
Other Investing Activities, net	268	282	322	367	361	422	295	317	339	342
Net Cash From Financing Activities	-440	-711	-706	-55	-576	-576	-151	-966	-	-674
Net Cash From Continuing Financing Activities	-440	-711	-706	-55	-576	-576	-151	-966	-	-674
Repayment of Debt	-440	-711	-3,157	-55	-1,276	-576	-9.00	-966	-	-674
Other Net Changes in Cash	-84	146	12	-77	-33	68	-104	-49	100	-121

This table presents Teva Pharmaceutical Industries' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	54,233	93,057	70,615	60,683	57,470	50,640	47,666	44,011	43,479	39,326
Total Current Assets	18,398	17,228	15,382	13,794	13,464	13,005	12,573	12,051	12,485	12,552
Cash & Equivalents	6,946	988	963	1,782	1,975	2,177	2,165	2,801	3,226	3,300
Accounts Receivable	5,350	7,523	7,128	5,822	5,676	4,581	4,529	3,696	3,408	3,059
Inventories, net	3,966	4,954	4,924	4,731	4,422	4,403	3,818	3,833	4,021	3,007
Prepaid Expenses	910	1,629	1,100	899	870	945	1,075	1,162	1,255	1,006
Other Current Assets	491	2,134	701	468	434	710	965	549	504	409
Other Current Nonoperating Assets	-	-	566	92	87	189	19	10	70	1,771
Plant, Property, & Equipment, net	6,544	8,073	7,673	6,868	6,436	6,296	5,982	5,739	5,750	4,581
Total Noncurrent Assets	29,291	67,756	47,560	40,021	37,569	31,339	29,112	26,221	25,243	22,193
Goodwill	19,025	44,409	28,414	24,917	24,846	20,624	20,040	17,633	17,177	15,147
Intangible Assets	7,675	21,487	17,640	14,005	11,232	8,923	7,466	6,270	5,387	4,418
Noncurrent Deferred & Refundable Income Taxes	250	625	574	368	386	695	596	1,458	1,812	1,799
Other Noncurrent Operating Assets	2,341	1,235	932	731	1,105	1,097	1,010	860	867	829
Total Liabilities & Shareholders' Equity	54,233	93,057	70,615	60,683	57,470	50,640	47,666	44,011	43,479	39,326
Total Liabilities	24,306	58,064	51,870	44,889	42,407	39,579	36,422	35,413	35,353	33,606
Total Current Liabilities	13,005	18,488	17,921	14,322	13,674	13,164	11,027	11,469	12,247	12,796
Short-Term Debt	1,585	3,276	3,646	2,216	2,345	3,188	1,426	2,109	1,672	1,781
Accounts Payable	1,918	2,157	2,069	1,853	1,718	1,756	1,686	1,887	2,602	2,203
Accrued Expenses	1,681	3,405	3,014	1,868	1,869	1,780	2,208	2,151	2,771	2,792
Current Employee Benefit Liabilities	-	-	549	870	693	685	563	566	611	624
Other Current Liabilities	7,821	9,534	8,605	7,515	7,048	5,757	5,144	4,755	4,579	4,698
Other Current Nonoperating Liabilities	0.00	116	38	-	-	-	-	-	13	698
Total Noncurrent Liabilities	11,301	39,576	33,949	30,567	28,733	26,414	25,395	23,944	23,106	20,809
Long-Term Debt	8,358	32,524	28,829	26,700	24,562	22,731	21,617	19,103	18,161	16,002
Noncurrent Deferred & Payable Income Tax Liabilities	1,748	5,413	3,277	2,140	1,096	964	784	548	606	483
Other Noncurrent Operating Liabilities	1,195	1,639	1,843	1,727	3,075	2,719	2,994	4,294	4,339	4,324
Commitments & Contingencies	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	-	-	-	-	0.00	340
Total Equity & Noncontrolling Interests	29,927	34,993	18,745	15,794	15,063	11,061	11,244	8,598	8,126	5,380
Total Preferred & Common Equity	29,769	33,337	17,359	14,707	13,972	10,026	10,278	7,804	7,506	5,373
Total Common Equity	26,478	29,717	13,728	14,707	13,972	10,027	10,278	7,804	7,505	5,373
Common Stock	17,809	23,463	23,533	27,266	27,368	27,500	27,618	27,745	27,864	27,822
Retained Earnings	14,851	13,607	-3,803	-5,958	-6,956	-10,946	-10,529	-12,975	-13,534	-15,173
Treasury Stock	-4,227	-4,194	-4,149	-4,142	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128
Accumulated Other Comprehensive Income / (Loss)	-1,955	-3,159	-1,853	-2,459	-2,312	-2,399	-2,683	-2,838	-2,697	-3,148
Noncontrolling Interest	158	1,656	1,386	1,087	1,091	1,035	966	794	620	7.00

This table presents Teva Pharmaceutical Industries' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	44,252	43,456	43,095	42,088	42,773	41,338	41,758
Total Current Assets	11,453	11,501	12,088	11,425	12,297	11,632	12,314
Cash & Equivalents	2,225	2,143	2,669	2,249	2,991	2,258	3,319
Accounts Receivable	3,730	3,435	3,539	3,385	3,456	3,766	3,462
Inventories, net	3,859	4,118	4,109	4,051	3,949	3,927	3,959
Prepaid Expenses	1,045	1,253	1,228	1,168	1,336	1,096	1,127
Other Current Assets	579	542	486	520	495	517	445
Other Current Nonoperating Assets	16	10	56	51	70	69	2.00
Plant, Property, & Equipment, net	5,568	5,751	5,712	5,622	5,618	5,573	5,672
Total Noncurrent Assets	27,232	26,205	25,295	25,041	24,857	24,133	23,773
Goodwill	18,433	17,799	17,118	16,885	17,007	16,488	16,124
Intangible Assets	6,393	5,964	5,738	5,525	5,056	4,853	4,756
Noncurrent Deferred & Refundable Income Taxes	1,546	1,572	1,578	1,748	1,960	2,000	2,070
Other Noncurrent Operating Assets	860	870	861	883	834	792	823
Total Liabilities & Shareholders' Equity	44,252	43,456	43,095	42,088	42,773	41,338	41,758
Total Liabilities	34,734	34,844	35,387	34,576	35,230	34,774	35,375
Total Current Liabilities	11,534	10,411	11,843	11,394	13,792	13,037	13,797
Short-Term Debt	2,769	1,023	1,980	1,479	3,060	2,094	2,580
Accounts Payable	1,635	2,381	2,508	2,280	2,439	2,366	2,371
Accrued Expenses	2,041	2,267	2,498	2,741	2,784	2,840	2,984
Current Employee Benefit Liabilities	496	432	451	530	492	492	619
Other Current Liabilities	4,593	4,309	4,406	4,362	4,755	4,891	5,026
Other Current Nonoperating Liabilities	-	-	-	-	262	356	216
Total Noncurrent Liabilities	23,200	24,433	23,543	23,182	21,438	21,737	21,578
Long-Term Debt	18,497	19,668	18,698	18,495	16,584	16,547	16,400
Noncurrent Deferred & Payable Income Tax Liabilities	503	550	534	544	569	553	538
Other Noncurrent Operating Liabilities	4,200	4,214	4,311	4,142	4,285	4,637	4,639
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	9,519	8,612	7,708	7,512	7,543	6,563	6,383
Total Preferred & Common Equity	8,767	7,860	7,052	6,929	7,278	6,359	6,065
Total Common Equity	8,768	7,861	7,050	6,929	7,278	6,359	6,065
Common Stock	27,709	27,776	27,805	27,837	27,854	27,887	27,918
Retained Earnings	-11,660	-13,086	-13,950	-13,870	-13,673	-14,519	-14,956
Treasury Stock	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128
Accumulated Other Comprehensive Income / (Loss)	-3,153	-2,701	-2,677	-2,910	-2,775	-2,881	-2,769
Noncontrolling Interest	751	751	656	582	265	204	319

This table displays calculated financial ratios and metrics derived from Teva Pharmaceutical Industries' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-3.06%	11.45%	-0.23%	-16.39%	-7.57%	-1.35%	-4.69%	-6.00%	6.17%	4.40%
EBITDA Growth	-28.88%	-35.85%	-792.80%	95.36%	160.61%	-723.41%	169.78%	-193.31%	128.52%	-142.53%
EBIT Growth	-35.35%	-64.97%	-2,330.46%	85.88%	51.27%	-248.30%	114.93%	-580.70%	80.27%	-105.77%
NOPAT Growth	-26.01%	-67.65%	-1,645.18%	90.64%	72.94%	-706.32%	146.62%	-231.93%	119.71%	-169.98%
Net Income Growth	-47.50%	-80.53%	-5,389.07%	84.97%	59.55%	-309.90%	111.12%	-648.03%	75.39%	-218.54%
EPS Growth	-48.88%	-96.15%	-23,328.57%	85.55%	61.28%	-300.00%	110.44%	-678.95%	77.27%	-190.00%
Operating Cash Flow Growth	8.09%	-29.81%	-42.80%	9.93%	-69.42%	62.57%	-34.38%	99.25%	-13.96%	-8.85%
Free Cash Flow Firm Growth	-82.62%	-3,792.71%	121.97%	-27.74%	-54.45%	6.75%	31.57%	-3.04%	-26.25%	102.73%
Invested Capital Growth	4.67%	112.37%	-28.88%	-13.86%	-6.84%	-13.27%	-7.25%	-15.90%	-8.62%	-22.46%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-4.64%	3.00%	-0.08%	-2.19%	-1.43%	3.76%	-1.36%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	92.77%	115.62%	5.10%	-16.26%	-126.77%	146.57%	-142.86%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	79.09%	72.58%	3.80%	-32.09%	-47.80%	73.21%	-141.81%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	85.75%	88.20%	6.71%	-26.71%	-88.42%	133.93%	-162.99%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	77.44%	76.84%	2.06%	-40.70%	-91.49%	74.67%	-61.10%
EPS Q/Q Growth	0.00%	0.00%	0.00%	78.42%	76.61%	0.82%	-42.42%	-89.66%	76.19%	-72.62%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	-16.75%	29.64%	-14.55%	18.57%	48.18%	18.24%	-32.81%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-23.69%	-23.56%	34.51%	-5.38%	6.71%	63.31%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-8.21%	-1.72%	1.00%	-3.10%	-5.42%	-2.04%	-14.06%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	57.79%	53.20%	48.57%	45.41%	44.63%	46.38%	47.83%	46.72%	48.25%	48.74%
EBITDA Margin	18.62%	10.72%	-74.44%	-4.13%	2.71%	-17.10%	12.52%	-12.43%	3.34%	-1.36%
Operating Margin	17.06%	9.83%	-80.01%	-8.96%	-2.62%	-21.44%	10.81%	-14.72%	2.73%	-1.83%
EBIT Margin	11.97%	3.76%	-84.10%	-14.21%	-7.49%	-26.45%	4.14%	-21.19%	-3.94%	-7.76%
Profit (Net Income) Margin	8.13%	1.42%	-75.27%	-13.53%	-5.92%	-24.61%	2.87%	-16.74%	-3.88%	-11.84%
Tax Burden Percent	67.90%	37.74%	89.50%	95.22%	79.05%	93.03%	69.30%	79.01%	98.56%	152.57%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	26.96%	63.23%	0.00%	0.00%	0.00%	0.00%	32.07%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	7.61%	1.54%	-20.46%	-2.48%	-0.75%	-6.71%	3.49%	-5.20%	1.17%	-0.97%
ROIC Less NNEP Spread (ROIC-NNEP)	-7.74%	-1.00%	-33.23%	-7.05%	-3.41%	-13.32%	0.30%	-10.10%	-4.08%	-12.63%
Return on Net Nonoperating Assets (RNNOA)	-1.61%	-0.58%	-40.76%	-11.84%	-5.73%	-24.67%	0.59%	-19.98%	-8.53%	-27.33%
Return on Equity (ROE)	5.99%	0.96%	-61.22%	-14.31%	-6.48%	-31.38%	4.09%	-25.19%	-7.35%	-28.30%
Cash Return on Invested Capital (CROIC)	3.05%	-70.41%	13.29%	12.42%	6.33%	7.50%	11.02%	12.06%	10.18%	24.34%
Operating Return on Assets (OROA)	4.67%	1.12%	-22.46%	-3.95%	-2.14%	-8.15%	1.34%	-6.90%	-1.43%	-3.10%
Return on Assets (ROA)	3.17%	0.42%	-20.10%	-3.77%	-1.69%	-7.58%	0.93%	-5.45%	-1.41%	-4.73%
Return on Common Equity (ROCE)	5.60%	0.83%	-49.49%	-11.78%	-6.02%	-28.83%	3.72%	-22.95%	-6.73%	-26.32%
Return on Equity Simple (ROE_SIMPLE)	5.36%	0.93%	-94.76%	-16.81%	-7.16%	-40.88%	4.44%	-32.02%	-8.19%	-36.46%
Net Operating Profit after Tax (NOPAT)	2,448	792	-12,239	-1,146	-310	-2,500	1,166	-1,538	303	-212
NOPAT Margin	12.46%	3.62%	-56.01%	-6.27%	-1.84%	-15.01%	7.34%	-10.30%	1.91%	-1.28%
Net Nonoperating Expense Percent (NNEP)	15.34%	2.54%	12.78%	4.57%	2.66%	6.61%	3.20%	4.90%	5.25%	11.66%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-5.16%	1.08%	-0.92%
Cost of Revenue to Revenue	42.21%	46.80%	51.42%	54.59%	55.37%	53.62%	52.17%	53.28%	51.75%	51.26%
SG&A Expenses to Revenue	6.92%	6.35%	6.64%	7.10%	7.06%	7.04%	6.92%	7.91%	7.33%	7.02%
R&D to Revenue	7.76%	9.48%	8.14%	6.64%	5.98%	5.98%	6.09%	5.61%	6.01%	6.03%
Operating Expenses to Revenue	40.73%	43.37%	128.58%	54.36%	47.26%	67.81%	37.03%	61.44%	45.52%	50.57%
Earnings before Interest and Taxes (EBIT)	2,352	824	-18,379	-2,596	-1,265	-4,406	658	-3,163	-624	-1,284
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,660	2,348	-16,267	-754	457	-2,849	1,988	-1,855	529	-225
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.23	1.20	1.55	1.07	0.77	1.05	0.86	1.30	1.56	4.65
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.00	1.63	0.97	0.86	0.63	0.63	0.56	0.68	0.74	1.51
Price to Earnings (P/E)	37.54	523.92	0.00	0.00	0.00	0.00	21.19	0.00	0.00	0.00
Dividend Yield	2.21%	3.88%	4.49%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.66%	0.19%	0.00%	0.00%	0.00%	0.00%	4.72%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.99	1.08	1.16	1.03	0.92	1.02	0.96	1.09	1.17	2.08
Enterprise Value to Revenue (EV/Rev)	3.33	3.46	2.65	2.40	2.17	2.12	1.93	1.97	1.83	2.41
Enterprise Value to EBITDA (EV/EBITDA)	17.89	32.25	0.00	0.00	80.36	0.00	15.43	0.00	54.69	0.00
Enterprise Value to EBIT (EV/EBIT)	27.85	91.89	0.00	0.00	0.00	0.00	46.62	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	26.75	95.59	0.00	0.00	0.00	0.00	26.32	0.00	95.45	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	11.82	19.46	25.98	17.96	49.10	29.07	38.45	18.45	21.15	31.92
Enterprise Value to Free Cash Flow (EV/FCFF)	66.80	0.00	7.27	7.64	14.03	12.65	8.34	8.23	11.00	7.47
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.33	1.02	1.73	1.83	1.79	2.34	2.05	2.47	2.44	3.11
Long-Term Debt to Equity	0.28	0.93	1.54	1.69	1.63	2.06	1.92	2.22	2.23	2.80
Financial Leverage	0.21	0.58	1.23	1.68	1.68	1.85	1.99	1.98	2.09	2.16
Leverage Ratio	1.89	2.27	3.05	3.80	3.83	4.14	4.41	4.62	5.23	5.98
Compound Leverage Factor	1.89	2.27	3.05	3.80	3.83	4.14	4.41	4.62	5.23	5.98
Debt to Total Capital	24.94%	50.57%	63.40%	64.67%	64.11%	70.09%	67.21%	71.16%	70.94%	75.66%
Short-Term Debt to Total Capital	3.98%	4.63%	7.12%	4.96%	5.59%	8.62%	4.16%	7.07%	5.98%	7.58%
Long-Term Debt to Total Capital	20.96%	45.94%	56.28%	59.72%	58.52%	61.47%	63.05%	64.08%	64.96%	68.08%
Preferred Equity to Total Capital	8.25%	5.11%	7.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.40%	2.34%	2.71%	2.43%	2.60%	2.80%	2.82%	2.66%	2.22%	1.48%
Common Equity to Total Capital	66.41%	41.98%	26.80%	32.89%	33.29%	27.11%	29.98%	26.18%	26.84%	22.86%
Debt to EBITDA	2.72	15.25	-2.00	-38.35	58.88	-9.10	11.59	-11.44	37.49	-79.04
Net Debt to EBITDA	0.82	14.83	-1.94	-35.99	54.56	-8.33	10.50	-9.93	31.39	-64.37
Long-Term Debt to EBITDA	2.28	13.85	-1.77	-35.41	53.75	-7.98	10.87	-10.30	34.33	-71.12
Debt to NOPAT	4.06	45.20	-2.65	-25.23	-86.77	-10.37	19.77	-13.79	65.43	-83.84
Net Debt to NOPAT	1.22	43.95	-2.57	-23.68	-80.40	-9.50	17.91	-11.97	54.79	-68.28
Long-Term Debt to NOPAT	3.41	41.06	-2.36	-23.30	-79.21	-9.09	18.54	-12.42	59.92	-75.45
Altman Z-Score	2.47	0.82	-0.42	0.22	0.20	-0.10	0.25	-0.12	0.09	0.21
Noncontrolling Interest Sharing Ratio	6.55%	13.44%	19.15%	17.67%	7.06%	8.13%	8.97%	8.87%	8.46%	6.99%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.41	0.93	0.86	0.96	0.98	0.99	1.14	1.05	1.02	0.98
Quick Ratio	0.95	0.46	0.45	0.53	0.56	0.51	0.61	0.57	0.54	0.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	980	-36,205	7,953	5,747	2,618	2,795	3,677	3,565	2,629	5,330
Operating Cash Flow to CapEx	717.88%	431.74%	254.58%	375.73%	142.48%	210.38%	141.99%	290.15%	260.08%	250.40%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.39	0.30	0.27	0.28	0.29	0.31	0.32	0.33	0.36	0.40
Accounts Receivable Turnover	3.65	3.40	2.98	2.82	2.94	3.25	3.49	3.63	4.46	5.12
Inventory Turnover	1.99	2.30	2.28	2.07	2.04	2.02	2.02	2.08	2.09	2.41
Fixed Asset Turnover	3.01	3.00	2.78	2.51	2.54	2.62	2.59	2.55	2.76	3.20
Accounts Payable Turnover	3.26	5.03	5.32	5.09	5.24	5.14	4.81	4.45	3.65	3.53
Days Sales Outstanding (DSO)	99.91	107.26	122.35	129.35	124.26	112.37	104.71	100.57	81.82	71.34
Days Inventory Outstanding (DIO)	183.40	158.82	160.43	176.65	178.64	180.29	181.11	175.59	174.80	151.23
Days Payable Outstanding (DPO)	111.95	72.55	68.63	71.76	69.69	70.97	75.83	82.00	99.91	103.40
Cash Conversion Cycle (CCC)	171.36	193.52	214.15	234.24	233.20	221.69	209.99	194.16	156.71	119.17
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	32,924	69,921	49,729	42,836	39,908	34,613	32,102	26,999	24,673	19,131
Invested Capital Turnover	0.61	0.43	0.37	0.39	0.41	0.45	0.48	0.51	0.61	0.76
Increase / (Decrease) in Invested Capital	1,468	36,997	-20,192	-6,893	-2,928	-5,295	-2,511	-5,103	-2,326	-5,542
Enterprise Value (EV)	65,494	75,714	57,801	43,930	36,725	35,353	30,679	29,334	28,930	39,802
Market Capitalization	59,048	35,626	21,272	15,709	10,702	10,576	8,835	10,129	11,703	24,972
Book Value per Share	$27.68	$29.25	$12.23	$14.44	$12.79	$9.15	$9.32	$7.03	$6.70	$4.74
Tangible Book Value per Share	($0.23)	($35.61)	($28.80)	($23.77)	($20.24)	($17.81)	($15.62)	($14.50)	($13.43)	($12.53)
Total Capital	39,870	70,793	51,220	44,710	41,970	36,980	34,287	29,810	27,959	23,503
Total Debt	9,943	35,800	32,475	28,916	26,907	25,919	23,043	21,212	19,833	17,783
Total Long-Term Debt	8,358	32,524	28,829	26,700	24,562	22,731	21,617	19,103	18,161	16,002
Net Debt	2,997	34,812	31,512	27,134	24,932	23,742	20,878	18,411	16,607	14,483
Capital Expenditures (CapEx)	772	901	874	651	525	578	562	548	526	498
Debt-free, Cash-free Net Working Capital (DFCFNWC)	32	1,028	144	-94	160	852	807	-110	-1,316	-1,763
Debt-free Net Working Capital (DFNWC)	6,978	2,016	1,107	1,688	2,135	3,029	2,972	2,691	1,910	1,537
Net Working Capital (NWC)	5,393	-1,260	-2,539	-528	-210	-159	1,546	582	238	-244
Net Nonoperating Expense (NNE)	851	481	4,210	1,326	690	1,599	710	961	918	1,747
Net Nonoperating Obligations (NNO)	2,997	34,928	30,984	27,042	24,845	23,552	20,858	18,401	16,547	13,411
Total Depreciation and Amortization (D&A)	1,308	1,524	2,112	1,842	1,722	1,557	1,330	1,308	1,153	1,059
Debt-free, Cash-free Net Working Capital to Revenue	0.16%	4.69%	0.66%	-0.51%	0.95%	5.11%	5.08%	-0.74%	-8.30%	-10.66%
Debt-free Net Working Capital to Revenue	35.51%	9.20%	5.07%	9.24%	12.64%	18.18%	18.72%	18.03%	12.05%	9.29%
Net Working Capital to Revenue	27.44%	-5.75%	-11.62%	-2.89%	-1.24%	-0.95%	9.74%	3.90%	1.50%	-1.47%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.84	$0.00	($16.26)	($2.35)	($0.91)	($3.64)	$0.38	($2.12)	($0.50)	($1.45)
Adjusted Weighted Average Basic Shares Outstanding	855M	0.00	1.02B	1.02B	1.09B	1.10B	1.10B	1.11B	1.12B	1.13B
Adjusted Diluted Earnings per Share	$1.82	$0.00	($16.26)	($2.35)	($0.91)	($3.64)	$0.38	($2.12)	($0.50)	($1.45)
Adjusted Weighted Average Diluted Shares Outstanding	1.02B	0.00	1.12B	1.02B	1.09B	1.10B	1.11B	1.11B	1.12B	1.13B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.02B	0.00	1.12B	1.09B	1.09B	1.10B	1.10B	1.11B	1.12B	1.13B
Normalized Net Operating Profit after Tax (NOPAT)	3,768	3,760	3,633	2,212	1,958	2,168	2,173	1,958	2,271	2,364
Normalized NOPAT Margin	19.18%	17.17%	16.62%	12.11%	11.59%	13.01%	13.68%	13.12%	14.33%	14.29%
Pre Tax Income Margin	11.97%	3.76%	-84.10%	-14.21%	-7.49%	-26.45%	4.14%	-21.19%	-3.94%	-7.76%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	72.32%	500.96%	-7.29%	-0.89%	-5.20%	0.00%	0.00%	0.00%	0.00%	-3.98%
Augmented Payout Ratio	99.81%	500.96%	-7.29%	-0.89%	-5.20%	0.00%	0.00%	0.00%	0.00%	-3.98%

This table displays calculated financial ratios and metrics derived from Teva Pharmaceutical Industries' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-7.51%	-5.27%	0.00%	2.43%	7.09%	14.78%	4.32%	7.37%	12.52%	-5.12%
EBITDA Growth	-31.36%	-720.14%	104.78%	22.44%	-28.69%	186.45%	-732.26%	102.09%	-118.39%	-97.15%
EBIT Growth	-56.28%	-581.25%	71.88%	20.52%	-61.08%	142.20%	-71.43%	73.32%	-596.92%	-148.81%
NOPAT Growth	-70.16%	-1,338.96%	98.18%	31.09%	174.43%	204.12%	-1,576.92%	99.24%	-108.74%	-102.92%
Net Income Growth	-80.79%	-785.53%	73.42%	-249.81%	32.76%	134.70%	-65.61%	3.53%	-606.49%	-159.10%
EPS Growth	-80.77%	-742.86%	76.74%	-271.43%	20.00%	135.59%	40.00%	3.85%	-750.00%	-145.24%
Operating Cash Flow Growth	2.65%	113.38%	-195.92%	163.41%	-99.08%	21.69%	14.48%	-68.21%	13,760.00%	-51.44%
Free Cash Flow Firm Growth	188.23%	72.92%	44.69%	6.86%	-20.44%	-31.88%	-31.76%	-34.78%	-23.22%	82.76%
Invested Capital Growth	-13.84%	-15.90%	-12.38%	-13.99%	-11.76%	-8.62%	-10.18%	-9.46%	-11.62%	-22.46%
Revenue Q/Q Growth	-5.04%	8.01%	-5.72%	5.93%	-0.72%	15.77%	-14.31%	9.03%	4.03%	-2.38%
EBITDA Q/Q Growth	160.85%	-282.99%	103.47%	-2,106.45%	155.95%	121.84%	-126.52%	106.63%	-592.31%	134.38%
EBIT Q/Q Growth	114.40%	-817.96%	77.23%	-237.73%	107.05%	678.46%	-198.94%	47.44%	-31.30%	23.53%
NOPAT Q/Q Growth	122.42%	-548.42%	98.64%	-4,930.77%	189.27%	70.13%	-123.09%	97.71%	-920.00%	43.14%
Net Income Q/Q Growth	122.39%	-2,420.69%	81.20%	-258.10%	108.50%	506.49%	-196.77%	-108.59%	55.38%	29.23%
EPS Q/Q Growth	123.81%	-2,460.00%	83.05%	-290.00%	107.69%	600.00%	-131.58%	-525.00%	48.00%	51.28%
Operating Cash Flow Q/Q Growth	341.46%	79.19%	-114.90%	323.45%	-98.46%	23,580.00%	-110.47%	183.06%	572.82%	-17.03%
Free Cash Flow Firm Q/Q Growth	36.05%	-6.29%	-13.72%	-2.87%	1.30%	-19.77%	-12.92%	-7.16%	19.25%	90.98%
Invested Capital Q/Q Growth	-4.33%	-5.42%	0.56%	-5.49%	-1.84%	-2.04%	-1.11%	-4.73%	-4.18%	-14.06%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	46.43%	45.58%	43.21%	46.31%	48.08%	54.21%	46.37%	48.61%	49.58%	50.15%
EBITDA Margin	13.57%	-23.00%	0.85%	-16.04%	9.04%	17.32%	-5.13%	0.31%	-1.48%	0.52%
Operating Margin	11.66%	-24.57%	-0.36%	-16.86%	8.96%	16.94%	-5.71%	-0.12%	-1.18%	-0.69%
EBIT Margin	4.65%	-30.88%	-7.46%	-23.78%	1.69%	11.35%	-12.25%	-5.91%	-7.46%	-5.84%
Profit (Net Income) Margin	1.61%	-34.66%	-6.91%	-23.36%	2.00%	10.48%	-10.97%	-20.99%	-9.00%	-6.53%
Tax Burden Percent	34.94%	112.35%	93.01%	98.16%	118.46%	92.29%	89.72%	355.28%	120.37%	111.74%
Interest Burden Percent	99.40%	99.92%	99.63%	100.11%	100.00%	100.00%	99.79%	100.00%	100.31%	100.00%
Effective Tax Rate	64.46%	0.00%	0.00%	0.00%	-18.46%	7.91%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	2.03%	-8.69%	-0.13%	-6.39%	6.03%	9.57%	-2.48%	-0.06%	-0.58%	-0.36%
ROIC Less NNEP Spread (ROIC-NNEP)	1.59%	-12.14%	-1.37%	-8.75%	4.23%	8.26%	-3.99%	-5.08%	-2.69%	-2.07%
Return on Net Nonoperating Assets (RNNOA)	3.08%	-24.02%	-2.85%	-18.94%	9.11%	17.26%	-8.73%	-12.34%	-6.51%	-4.48%
Return on Equity (ROE)	5.11%	-32.71%	-2.98%	-25.33%	15.14%	26.83%	-11.22%	-12.39%	-7.09%	-4.84%
Cash Return on Invested Capital (CROIC)	12.22%	12.06%	9.59%	12.01%	9.17%	10.18%	11.35%	12.44%	13.76%	24.34%
Operating Return on Assets (OROA)	1.53%	-10.05%	-2.46%	-8.02%	0.60%	4.11%	-4.55%	-2.28%	-2.98%	-2.33%
Return on Assets (ROA)	0.53%	-11.29%	-2.28%	-7.88%	0.71%	3.80%	-4.07%	-8.10%	-3.60%	-2.61%
Return on Common Equity (ROCE)	4.69%	-29.81%	-2.72%	-23.24%	13.96%	24.56%	-10.51%	-11.64%	-6.63%	-4.50%
Return on Equity Simple (ROE_SIMPLE)	-14.89%	0.00%	-22.90%	-34.70%	-35.04%	0.00%	-10.73%	-11.78%	-20.05%	0.00%
Net Operating Profit after Tax (NOPAT)	149	-668	-9.10	-458	409	695	-153	-3.50	-36	-20
NOPAT Margin	4.14%	-17.20%	-0.25%	-11.81%	10.62%	15.60%	-4.00%	-0.08%	-0.82%	-0.48%
Net Nonoperating Expense Percent (NNEP)	0.45%	3.46%	1.24%	2.36%	1.81%	1.31%	1.51%	5.03%	2.11%	1.71%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.24%	-	-	-	2.49%	-	-	-	-0.09%
Cost of Revenue to Revenue	53.57%	54.42%	56.79%	53.69%	51.92%	45.77%	53.63%	51.39%	50.39%	49.89%
SG&A Expenses to Revenue	7.87%	7.42%	8.09%	7.92%	6.96%	6.53%	7.28%	6.80%	6.88%	7.14%
R&D to Revenue	4.87%	5.41%	6.39%	6.19%	6.57%	5.07%	6.34%	6.46%	5.54%	5.84%
Operating Expenses to Revenue	34.77%	70.10%	43.57%	63.18%	39.12%	37.29%	52.06%	48.75%	50.74%	50.84%
Earnings before Interest and Taxes (EBIT)	167	-1,199	-273	-922	65	506	-468	-246	-323	-247
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	488	-893	31	-622	348	772	-196	13	-64	22
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.02	1.30	1.25	1.20	1.65	1.56	2.17	2.89	3.37	4.65
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.59	0.68	0.66	0.56	0.75	0.74	0.99	1.13	1.22	1.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.01	1.09	1.07	1.06	1.18	1.17	1.34	1.51	1.63	2.08
Enterprise Value to Revenue (EV/Rev)	1.90	1.97	1.95	1.80	1.95	1.83	2.05	2.15	2.17	2.41
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	54.69	108.39	37.35	69.32	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	95.45	205.11	57.00	108.09	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	26.80	18.45	19.50	15.99	25.70	21.15	23.57	29.96	19.61	31.92
Enterprise Value to Free Cash Flow (EV/FCFF)	7.63	8.23	10.45	8.13	12.07	11.00	11.20	11.50	11.15	7.47
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.23	2.47	2.40	2.68	2.66	2.44	2.60	2.84	2.97	3.11
Long-Term Debt to Equity	1.94	2.22	2.28	2.43	2.46	2.23	2.20	2.52	2.57	2.80
Financial Leverage	1.94	1.98	2.08	2.16	2.16	2.09	2.19	2.43	2.41	2.16
Leverage Ratio	4.39	4.62	4.80	5.08	5.07	5.23	5.34	5.92	6.03	5.98
Compound Leverage Factor	4.37	4.62	4.78	5.08	5.07	5.23	5.33	5.92	6.05	5.98
Debt to Total Capital	69.08%	71.16%	70.61%	72.85%	72.67%	70.94%	72.26%	73.96%	74.83%	75.66%
Short-Term Debt to Total Capital	8.99%	7.07%	3.49%	6.98%	5.38%	5.98%	11.26%	8.31%	10.17%	7.58%
Long-Term Debt to Total Capital	60.08%	64.08%	67.12%	65.87%	67.29%	64.96%	61.00%	65.65%	64.66%	68.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	2.44%	2.66%	2.56%	2.31%	2.12%	2.22%	0.97%	0.81%	1.26%	1.48%
Common Equity to Total Capital	28.48%	26.18%	26.83%	24.84%	25.21%	26.84%	26.77%	25.23%	23.91%	22.86%
Debt to EBITDA	-26.00	-11.44	-17.59	-20.76	-17.58	37.49	65.05	19.89	36.15	-79.04
Net Debt to EBITDA	-23.28	-9.93	-15.77	-18.08	-15.60	31.39	55.14	17.48	29.83	-64.37
Long-Term Debt to EBITDA	-22.61	-10.30	-16.72	-18.77	-16.28	34.33	54.91	17.66	31.24	-71.12
Debt to NOPAT	-26.05	-13.79	-19.75	-24.58	-22.36	65.43	123.08	30.36	56.37	-83.84
Net Debt to NOPAT	-23.33	-11.97	-17.70	-21.40	-19.84	54.79	104.34	26.69	46.51	-68.28
Long-Term Debt to NOPAT	-22.66	-12.42	-18.77	-22.22	-20.71	59.92	103.91	26.95	48.71	-75.45
Altman Z-Score	0.14	0.02	0.10	-0.03	0.11	0.17	0.12	0.16	0.18	0.30
Noncontrolling Interest Sharing Ratio	8.27%	8.87%	8.83%	8.26%	7.83%	8.46%	6.29%	6.04%	6.48%	6.99%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.99	1.05	1.10	1.02	1.00	1.02	0.89	0.89	0.89	0.98
Quick Ratio	0.52	0.57	0.54	0.52	0.49	0.54	0.47	0.46	0.49	0.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	4,733	4,435	3,827	3,717	3,766	3,021	2,611	2,425	2,891	5,522
Operating Cash Flow to CapEx	445.08%	685.21%	-104.32%	272.27%	3.36%	994.96%	-100.00%	106.19%	468.24%	445.74%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.33	0.33	0.34	0.35	0.36	0.37	0.39	0.40	0.40
Accounts Receivable Turnover	3.89	3.63	3.88	3.75	4.29	4.46	4.64	4.46	4.90	5.12
Inventory Turnover	1.97	2.08	2.00	2.01	2.09	2.09	2.03	2.05	2.10	2.41
Fixed Asset Turnover	2.61	2.55	2.56	2.62	2.73	2.76	2.82	2.89	2.97	3.20
Accounts Payable Turnover	5.01	4.45	3.93	3.72	4.23	3.65	3.39	3.38	3.62	3.53
Days Sales Outstanding (DSO)	93.73	100.57	94.01	97.34	85.02	81.82	78.58	81.84	74.50	71.34
Days Inventory Outstanding (DIO)	185.67	175.59	182.95	181.57	174.49	174.80	180.22	178.26	173.80	151.23
Days Payable Outstanding (DPO)	72.85	82.00	92.96	98.13	86.36	99.91	107.68	108.12	100.92	103.40
Cash Conversion Cycle (CCC)	206.55	194.16	184.00	180.78	173.15	156.71	151.12	151.98	147.39	119.17
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	28,545	26,999	27,151	25,661	25,188	24,673	24,387	23,233	22,261	19,131
Invested Capital Turnover	0.49	0.51	0.51	0.54	0.57	0.61	0.62	0.67	0.71	0.76
Increase / (Decrease) in Invested Capital	-4,584	-5,103	-3,836	-4,175	-3,357	-2,326	-2,764	-2,428	-2,927	-5,542
Enterprise Value (EV)	28,754	29,334	29,130	27,102	29,738	28,930	32,735	34,992	36,395	39,802
Market Capitalization	8,962	10,129	9,831	8,437	11,431	11,703	15,817	18,405	20,415	24,972
Book Value per Share	$7.90	$7.03	$7.08	$6.29	$6.18	$6.70	$6.48	$5.61	$5.35	$4.74
Tangible Book Value per Share	($14.46)	($14.50)	($14.31)	($14.11)	($13.81)	($13.43)	($13.17)	($13.23)	($13.08)	($12.53)
Total Capital	30,785	29,810	29,303	28,386	27,486	27,959	27,187	25,204	25,363	23,503
Total Debt	21,266	21,212	20,691	20,678	19,974	19,833	19,644	18,641	18,980	17,783
Total Long-Term Debt	18,497	19,103	19,668	18,698	18,495	18,161	16,584	16,547	16,400	16,002
Net Debt	19,041	18,411	18,548	18,009	17,725	16,607	16,653	16,383	15,661	14,483
Capital Expenditures (CapEx)	122	142	139	119	149	119	124	97	148	129
Debt-free, Cash-free Net Working Capital (DFCFNWC)	463	-110	-30	-444	-739	-1,316	-1,426	-1,569	-2,222	-1,763
Debt-free Net Working Capital (DFNWC)	2,688	2,691	2,113	2,225	1,510	1,910	1,565	689	1,097	1,537
Net Working Capital (NWC)	-81	582	1,090	245	31	238	-1,495	-1,405	-1,483	-244
Net Nonoperating Expense (NNE)	91	678	244	448	332	228	266	871	354	256
Net Nonoperating Obligations (NNO)	19,026	18,401	18,539	17,953	17,676	16,547	16,844	16,670	15,878	13,411
Total Depreciation and Amortization (D&A)	321	306	304	300	283	266	272	259	259	269
Debt-free, Cash-free Net Working Capital to Revenue	3.06%	-0.74%	-0.20%	-2.96%	-4.84%	-8.30%	-8.91%	-9.63%	-13.25%	-10.66%
Debt-free Net Working Capital to Revenue	17.75%	18.03%	14.16%	14.82%	9.89%	12.05%	9.78%	4.23%	6.54%	9.29%
Net Working Capital to Revenue	-0.54%	3.90%	7.30%	1.63%	0.20%	1.50%	-9.34%	-8.62%	-8.84%	-1.47%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.05	($1.18)	($0.18)	($0.77)	$0.07	$0.42	($0.12)	($0.75)	($0.39)	($0.19)
Adjusted Weighted Average Basic Shares Outstanding	1.11B	1.11B	1.12B	1.12B	1.12B	1.12B	1.12B	1.13B	1.13B	1.13B
Adjusted Diluted Earnings per Share	$0.05	($1.18)	($0.18)	($0.77)	$0.07	$0.42	($0.12)	($0.75)	($0.39)	($0.19)
Adjusted Weighted Average Diluted Shares Outstanding	1.12B	1.11B	1.12B	1.12B	1.14B	1.12B	1.12B	1.13B	1.13B	1.13B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.11B	1.11B	1.12B	1.12B	1.12B	1.12B	1.13B	1.13B	1.13B	1.13B
Normalized Net Operating Profit after Tax (NOPAT)	472	519	356	475	534	731	449	573	703	639
Normalized NOPAT Margin	13.12%	13.36%	9.71%	12.26%	13.87%	16.41%	11.75%	13.77%	16.22%	15.11%
Pre Tax Income Margin	4.62%	-30.85%	-7.43%	-23.80%	1.69%	11.35%	-12.23%	-5.91%	-7.48%	-5.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3.98%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3.98%

Frequently Asked Questions About Teva Pharmaceutical Industries' Financials

When does Teva Pharmaceutical Industries's financial year end?

According to the most recent income statement we have on file, Teva Pharmaceutical Industries' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Teva Pharmaceutical Industries' net income changed over the last 9 years?

Teva Pharmaceutical Industries' net income appears to be on a downward trend, with a most recent value of -$1.96 billion in 2024, falling from $1.60 billion in 2015. The previous period was -$615 million in 2023. Check out Teva Pharmaceutical Industries' forecast to explore projected trends and price targets.

What is Teva Pharmaceutical Industries's operating income?

Teva Pharmaceutical Industries's total operating income in 2024 was -$303 million, based on the following breakdown:

Total Gross Profit: $8.06 billion
Total Operating Expenses: $8.37 billion

How has Teva Pharmaceutical Industries revenue changed over the last 9 years?

Over the last 9 years, Teva Pharmaceutical Industries' total revenue changed from $19.65 billion in 2015 to $16.54 billion in 2024, a change of -15.8%.

How much debt does Teva Pharmaceutical Industries have?

Teva Pharmaceutical Industries' total liabilities were at $33.61 billion at the end of 2024, a 4.9% decrease from 2023, and a 38.3% increase since 2015.

How much cash does Teva Pharmaceutical Industries have?

In the past 9 years, Teva Pharmaceutical Industries' cash and equivalents has ranged from $963 million in 2017 to $6.95 billion in 2015, and is currently $3.30 billion as of their latest financial filing in 2024.

How has Teva Pharmaceutical Industries' book value per share changed over the last 9 years?

Over the last 9 years, Teva Pharmaceutical Industries' book value per share changed from 27.68 in 2015 to 4.74 in 2024, a change of -82.9%.

Related Companies

This page (NYSE:TEVA) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Teva Pharmaceutical Industries (TEVA) Financials

Frequently Asked Questions About Teva Pharmaceutical Industries' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Teva Pharmaceutical Industries (TEVA) Financials

Annual Income Statements for Teva Pharmaceutical Industries

Quarterly Income Statements for Teva Pharmaceutical Industries

Annual Cash Flow Statements for Teva Pharmaceutical Industries

Quarterly Cash Flow Statements for Teva Pharmaceutical Industries

Annual Balance Sheets for Teva Pharmaceutical Industries

Quarterly Balance Sheets for Teva Pharmaceutical Industries

Annual Metrics and Ratios for Teva Pharmaceutical Industries

Quarterly Metrics and Ratios for Teva Pharmaceutical Industries

Frequently Asked Questions About Teva Pharmaceutical Industries' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools